Prevalence of Gastrointestinal Cancers in India
Fig. 13.1 Gastrointestinal cancers in different parts of India Salient features of the review: Esophageal cancer is highest in northeastern region of India than other parts of the world for…
Gall Bladder Cancer: What Needs to Be Done in India?
© Springer International Publishing Switzerland 2015Varsha Gandhi, Kapil Mehta, Rajesh Grover, Sen Pathak and Bharat B. Aggarwal (eds.)Multi-Targeted Approach to Treatment of Cancer10.1007/978-3-319-12253-3_11 11. Gall Bladder Cancer: What Needs to Be Done in India? Vinay K. Kapoor1 (1) Sanjay Gandhi…
Chronic Lymphocytic Leukemia at the Genomic Level
© Springer International Publishing Switzerland 2015Varsha Gandhi, Kapil Mehta, Rajesh Grover, Sen Pathak and Bharat B. Aggarwal (eds.)Multi-Targeted Approach to Treatment of Cancer10.1007/978-3-319-12253-3_3 3. Chronic Lymphocytic Leukemia at the Genomic Level Hima V. Vangapandu1, 2 and Varsha Gandhi1, 2, 3 (1)…
Tumor-Associated Macrophages in Tumor Progression: From Bench to Bedside
Fig. 5.1 TAM in modulating cancer-related inflammation. TAM participate in many aspects of cancer growth and progression. More in details, they sustain tumor growth through the release of growth factors,…
Rational Combinations of mTOR Inhibitors as Anticancer Strategies
Fig. 9.1 (a) Feedback loops of the PI3K/Akt/mTOR pathway. Red line means inhibition and black activation; in blue: PI3k/Akt/mTOR pathway; in brown: MAPK pathway. (b) Two ways of blocking the…
The Clinical Pharmacology and Toxicity Profile of Rapalogs
Fig. 8.1 Chemical structures of sirolimus (a), temsirolimus (b), everolimus (c), and ridaforolimus (d) [4] Rapalogs retain the basic structure of the parent rapamycin compound, but differ by the moiety…
mTOR Inhibition Beyond Rapalogs
Fig. 12.1 The PI3K pathway and associated inhibitor classes. Schematic representation of the PI3K/Akt/mTOR pathway (red) and the MAPK pathway (blue) including recognized points of crosstalk between the respective cascades….
Predictive Biomarkers of Response to mTOR Inhibitors
Fig. 10.1 Oncogenic activation of mTOR may be related to multiple oncogenic activations, mutations of major anti-oncogenes as well as microenvironment-dependent parameters such as hypoxia and nutrient depletion Knowing how…
The PI3K-mTOR Pathway
Fig. 2.1 mTOR signaling pathway (detailed in text) 2.2.1.1 mTORC1 mTORC1 includes two unique binding partners: regulatory associated protein of mTOR (Raptor), which recognizes mTOR substrates through their TOR Signaling…
New Indications of mTOR Inhibitors in Rare Tumors
Clinical characteristic Diagnosis Major features Facial angiofibromas or forehead plaque Definite TSC: Either 2 major features or 1 major features plus 2 minor features Probable TSC: One major plus 1…
